Search results
Results from the WOW.Com Content Network
Aventis Pasteur, the vaccine division of the Sanofi-Aventis Group, changes its name to Sanofi Pasteur. 2008: Sanofi Pasteur acquires Acambis plc, a biotech company. 2009: Sanofi Pasteur acquires major stake in Hyderabad-based Shantha Biotechnics. [21] 2020: Sanofi Pasteur and GlaxoSmithKline have said they are starting clinical trials of their ...
Vaxigrip and its quadrivalent formulation Vaxigrip Tetra are split virus inactivated vaccines made by Sanofi Pasteur in Europe. [2] [26] Vaxigrip provides immune responses to three influenza strains and VaxigripTetra adds another B strain. VaxigripTetra was approved in Europe in 2016 except for infants younger than three years old. [2]
The Sanofi–GSK COVID-19 vaccine, sold under the brand name VidPrevtyn Beta, is a COVID-19 vaccine developed by Sanofi Pasteur and GSK. [4] [5] The Sanofi–GSK COVID‑19 vaccine was authorized for medical use in the European Union in November 2022. [1] [2] [6] [7]
The Sanofi–GSK COVID-19 vaccine, sold under the brand name VidPrevtyn Beta, is a subunit vaccine developed by Sanofi Pasteur and GSK plc. It is based on the SARS-CoV-2 Beta variant . EMA countries (as booster only) [ 707 ]
Vaccine Excipients Adenovirus vaccine: This list refers to the type 4 and type 7 adenovirus vaccine tablets licensed in the US: Acetone, alcohol, anhydrous lactose, castor oil, cellulose acetate phthalate, dextrose, D-fructose, D-mannose, FD&C Yellow #6 aluminium lake dye, fetal bovine serum, human serum albumin, magnesium stearate, micro crystalline cellulose, plasdone C, Polacrilin potassium ...
Sanofi Pasteur's vaccine approved by the United States in April 2007. [33] GlaxoSmithKline's vaccine Prepandrix approved by the European Union in May 2008. [34] CSL Limited's vaccine Panvax approved by Australia in June 2008. [35]
Flu vaccines used during the flu in 2009. This is a list of vaccine-related topics.. A vaccine is a biological preparation that improves immunity to a particular disease.A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe or its toxins.
Connaught was merged with Institut Mérieux in 1989, and in 1999, it was transformed into the Canadian component of "Pasteur Mérieux Connaught," owned by Rhône-Poulenc. A series of acquisitions since then have transferred ownership of what used to be the Connaught Laboratories to the global vaccine business of Sanofi.